3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
3
Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma in Situ
1
Interventions
Magnetic Resonance Imaging
2
Interferon beta-1b
2
Electrocardiography
2
Diphenhydramine
2
Acetaminophen
2
valrubicin
1
pembrolizumab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
dodecyl maltoside
1
apaziquone
1
aldesleukin
1
Tomography, X-Ray Computed
1
Respiratory Function Tests
1
Proflavine
1
Prochlorperazine
1
Positron-Emission Tomography
1
Ondansetron
1
O(6)-codeine methyl ether
1
Nicotine Replacement Therapy
1
Meperidine
1
Mastectomy, Subcutaneous
1
Loperamide
1
Interleukin-2
1
Innovar
1
Indomethacin
1
Imiquimod
1
Hydroxyzine
1
Histamine Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma in Situ
×
valrubicin
×
Clear all
NCT01316874
2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3
Completed
90 enrolled